ReviewFrontiers in dental medicine2026
Magnesium phosphate cements in regenerative dentistry: from biomaterial design to clinical translation.
Review in Frontiers in dental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnesium phosphate cements (MPCs) are emerging biomaterials in regenerative dentistry, offering rapid setting, high early mechanical strength, biodegradability, osteogenic potential, and intrinsic antimicrobial activity. Compared with conventional calcium phosphate cements (CPCs), MPCs demonstrate superior biological interactions and faster scaffold resorption, positioning them as promising candidates for endodontic, periodontal, craniofacial, and bone tissue engineering applications. This Mini Review critically appraises the chemistry, biological properties, clinical applications, and translational challenges of MPCs, highlighting current evidence gaps and emerging research directions. While preclinical evidence is encouraging, exothermic setting reactions, ammonia release in ammonium-containing formulations, and the absence of robust multicentre clinical trial data remain the principal barriers to widespread adoption. Advances in formulation engineering, additive manufacturing, and composite scaffold design represent the most promising avenues for addressing these limitations and facilitating clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.